Document is current
Any future updates will be listed below
-
Authors
Trivioli, Giorgio https://orcid.org/0000-0003-1578-4402
Casal Moura, Marta https://orcid.org/0000-0001-7439-6501
Kronbichler, Andreas https://orcid.org/0000-0002-2945-2946
Smith, Rona M.
Terrier, Benjamin
McAdoo, Stephen https://orcid.org/0000-0001-8260-8770
Jones, Rachel B. https://orcid.org/0000-0003-4790-283X
Merkel, Peter A.
Jayne, David R. W. https://orcid.org/0000-0002-1712-0637
- License Information
-
More Information
Article History
Accepted: 2 May 2025
First Online: 5 June 2025
Competing interests
: A.K. has received grant support from CSL Vifor and Otsuka and consultancy and speaking fees from Amgen, AstraZeneca, Boehringer Ingelheim, CSL Vifor, Delta4, GlaxoSmithKline, Miltenyi Biotec, Novartis, Novo Nordisk, Otsuka, Roche, Sobi and Walden Biosciences. B.T. has received consulting fees from AstraZeneca, GlaxoSmithKline, CSL Vifor, Novartis, LFB, Boehringer Ingelheim. R.M.S. has received research grants from GlaxoSmithKline and Union Therapeutics and speaking fees from Vifor. R.B.J. has received research funding from GSK, CSL Vifor, advisory board fees from CSL Vifor and GSK and honoraria from Roche. P.A.M. has received funds for the following activities in the past 2 years: consulting for AbbVie, Alpine, Amgen, ArGenx, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, CSL Behring, GlaxoSmithKline, iCell, Interius, Kinevant, Kyverna, Metagenomia, Neutrolis, Novartis, NS Pharma, Q32, Quell, Regeneron, Sanofi, Sparrow, Takeda, Vistera; research support from AbbVie, Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eicos, Electra, GlaxoSmithKline, Neutrolis, Takeda and stock options from Kyverna, Q32, Sparrow; royalties from UpToDate. D.R.W.J. has received research grants from Roche/Genentech and CSL Vifor, and consulting fees from Amgen, Alentis, Astra-Zeneca, Aurinia, BMS, Boehringer, GSK, Novartis, Roche, Takeda and CSL Vifor.
